Oral and Poster Abstracts
632. Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I
Research, Fundamental Science, Biological therapies, Clinical Research, CML, Chronic Myeloid Malignancies, Diseases, real-world evidence, Therapies, immunology, Myeloid Malignancies, Biological Processes, Vaccines
Alejandro ZURDO Castronuño1*, Miriam Solera Sainero2*, Magdalena Corona3*, Monserrat Torres4*, Guiomar Casado-Fernandez4*, Fernando Ramos-García5*, Javier Garcia-Pérez4*, María Aranzazú Murciano-Antón6*, María Jesús Blanchard, MD7*, Juan Marquet Palomanes, MD8*, Fernando Martin Moro, MD7*, Mayte Pérez-Olmeida9*, Javier López Jiménez, MD, PhD7*, Maria Teresa Coiras4*, Sara Rodriguez-Mora4* and Valentín Garcia-Gutiérrez, MD, PhD7
1Hematology and Hemotherapy service, HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL, MADRID, AL, Spain
2Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain., MADRID, Spain
3HOSPITAL UNIVERSITARIO RAMÓN Y CAJAL, Madrid, Spain
4Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain
5Instituto De Salud Carlos III, Majadahonda, ESP
6Family Medicine, Centro de Salud Doctor Pedro Laín Entralgo, Alcorcón, Spain
7Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain
8Hematology Service, Hospital Universitario Ramón y Cajal, Madrid, 28012, Spain
9Serology Laboratory, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain
Background: Patients with oncohematological malignancies have been excluded from the clinical trials in which the vaccines against COVID-19 were approved. Although there are some studies that have evaluated the immunologic and clinical response to SARS-CoV-2 in patients with different oncohematologic diseases, the response developed by patients with Chronic Myeloid Leukemia (CML) has been little explored.
Objective: To evaluate the immune and clinical response to vaccination against SARS-CoV-2 in patients with CML.